A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2018
Price : $35 *
At a glance
- Drugs Abemaciclib (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Ramucirumab (Primary) ; Samotolisib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms KEYNOTE-238
- Sponsors Eli Lilly
- 11 Sep 2018 Planned End Date changed from 1 Jul 2020 to 2 Jul 2020.
- 06 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2020.
- 06 Aug 2018 Results published in the Clinical Cancer Research.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History